Companies: 10,795·Total market cap: $144.5T

Impel Pharmaceuticals Inc.

Impel Pharmaceuticals Inc.

IMPLNASDAQHealthcare

$0.04

$-0.02(-27.27%)

Market Cap$956000

P/E Ratio—

52W High$4.2

52W Low$0.0212

Avg Volume1.0M

Open$0.05

Beta1.17

Impel Pharmaceuticals Inc. (IMPL) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

IMPL · net income · updated Jun 9, 2026

Core profitability metrics

IMPL · net income · margin · TTM · CAGR

Net income was −$129.4M for FY2022 (fiscal year ending 2022-12-31), down 69.1% year-over-year. Net profit margin was -1023.1%.

FY2022 Net Income−$129.4M▼ -69.1% YoY

Trailing 12M (TTM)−$96.1Mtrailing 4 quarters sum

Net Profit Margin< −999%−$129.4M ÷ $12.7M

YoY Change-69.1%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · IMPL net income history · IMPL profit margin

Annual net income data

IMPL · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2022Loss−$129.4M▼ 69.1%-1023.1%$12.7M

FY2021Loss−$76.5M▼ 67.1%-11457.5%$668,000

FY2020Loss−$45.8M▼ 9.4%—$0

FY2019Loss−$41.9M——$0

Net income vs peers (Healthcare)

IMPL vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Impel Pharmaceuticals Inc.YOU

IMPL

−$129.4M-69.1%-1023.1%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Impel Pharmaceuticals Inc. (IMPL) reported net income of −$129.4M for FY2022 (fiscal year ending 2022-12-31), down 69.1% year-over-year. The net profit margin was -1023.1% — meaning the company kept $-10.23 of every dollar of revenue as profit.

Impel Pharmaceuticals Inc. has not yet achieved annual profitability based on available data (4 fiscal years). The company has reported net losses across all available periods.

Impel Pharmaceuticals Inc.'s net profit margin was -1023.1% for FY2022, based on the latest annual results.

Investors sometimes search for "Impel Pharmaceuticals Inc. net worth" — the company's market capitalization is a separate figure from IMPL net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

IMPL net income · 4 questions

Impel Pharmaceuticals Inc. is not currently profitable on an annual basis. The company reported a net loss of $129.4M for FY2022.

is IMPL profitabledoes IMPL make a profitIMPL profitabilityIMPL profitable company

▸ Source: FMP /income-statement · GAAP · Impel Pharmaceuticals Inc. · Impel Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026